"text","label","instanceType","uuid:ID","id","description","name"
"To determine if there is a statistically significant relationship (overall Type 1 erroralpha=0.05) between the change in both the ADAS-Cog (11) and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg]).","","Objective","6e39b2c7-7d30-47f2-8b50-b0e2f97933c0","Objective_1","Main objective","OBJ1"
"To document the safety profile of the xanomeline TTS.","","Objective","9b4e61ea-558f-4966-9563-05e1c7458fb8","Objective_2","Safety","OBJ2"
"To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these
areas.","","Objective","d9a295e4-1230-4f4e-93bf-1598e024f81b","Objective_3","Behaviour","OBJ3"
"To assess the dose-dependent improvements in activities of daily living. Improved scores on the Disability Assessment for Dementia (DAD) will indicate improvement in these areas (see Attachment LZZT.5).","","Objective","1f901cc7-d2f0-4789-bf7d-4d4d6b638cd0","Objective_4","","OBJ4"
"To assess the dose-dependent improvements in an extended assessment of cognition that integrates attention/concentration tasks. The Alzheimer's Disease Assessment Scale-14 item Cognitive Subscale, hereafter referred to as ADAS-Cog (14), will be used for this assessment (see Attachment LZZT.2).","","Objective","aad872fe-268a-4b26-90c2-eed543955949","Objective_5","","OBJ5"
"To assess the treatment response as a function of Apo E genotype.","","Objective","0b305ca0-9413-462b-97ba-cdbb93ac2839","Objective_6","","OBJ6"
